Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Vaccinations

Vaccinations

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Acute Pharyngitis

Acute Pharyngitis

Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

US Preventive Services Task Force: What Does the Future Hold?

American family physician·2026

Same author

Advisory Committee on Immunization Practices Standards for Assessing Evidence.

JAMA·2025

Same author

Practice Alert: Meningococcal Vaccines.

American family physician·2025

Same author

Practice Alert: Pneumococcal Conjugate Vaccines Approved for Adults.

American family physician·2025

Same author

Practice Alert: CDC Guidelines on Doxycycline for STI Postexposure Prophylaxis.

American family physician·2024

Same author

Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

MMWR. Morbidity and mortality weekly report·2024

Search research articles

Related Experiment Video

Updated: Jan 1, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumococcal conjugate vaccine update.

Doug Campos-Outcalt¹

¹University of Arizona, Phoenix, USA.

The Journal of Family Practice

|December 21, 2019

Summary

This summary is machine-generated.

The Advisory Committee on Immunization Practices (ACIP) has updated recommendations, no longer advising routine pneumococcal conjugate vaccine (PCV13) for healthy adults aged 65 and older. New guidance clarifies dosing intervals for PCV13 and pneumococcal polysaccharide vaccine (PPSV23).

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Related Experiment Videos

Last Updated: Jan 1, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Area of Science:

Immunology
Vaccinology
Public Health

Background:

Pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23) are crucial for preventing pneumococcal disease.
Previous recommendations involved routine PCV13 vaccination for older adults.

Purpose of the Study:

To communicate updated ACIP recommendations regarding PCV13 use in older adults.
To provide clear guidelines on the timing of PCV13 and PPSV23 administration.

Main Methods:

Review of current epidemiological data and vaccine efficacy studies.
Analysis of ACIP's immunization schedule and expert committee deliberations.

Main Results:

Routine PCV13 vaccination is no longer recommended for immunocompetent adults aged 65 years and older.
Simplified guidance on the intervals between PCV13 and PPSV23 administration has been established.

Conclusions:

The updated recommendations aim to optimize pneumococcal vaccination strategies in older adults.
Clearer guidelines will facilitate appropriate vaccine use and improve public health outcomes.